| 0.125 0.073 (140.38%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.14 |
1-year : | 0.17 |
| Resists | First : | 0.12 |
Second : | 0.14 |
| Pivot price | 0.07 |
|||
| Supports | First : | 0.06 |
Second : | 0.02 |
| MAs | MA(5) : | 0.08 |
MA(20) : | 0.06 |
| MA(100) : | 0.48  |
MA(250) : | 1.42 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.4 |
D(3) : | 61.4 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 3.5 | Low : | 0.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZYXI ] has closed below upper band by 1.5%. Bollinger Bands are 80.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.13 - 0.13 | 0.13 - 0.13 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.12 | 0.12 - 0.13 |
Zynex, Inc., operating through its subsidiaries, specializes in the development, production, and sale of medical devices. These devices primarily utilize electrical stimulation to alleviate both chronic and acute pain, and to stimulate and exercise muscles for rehabilitation. The company's core product offerings include NexWave, a versatile, dual-channel device combining interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation (NMES), which is actively marketed to physicians and therapists by its field sales force. Other significant products are NeuroMove, an electrical stimulator activated by electromyography; InWave, specifically designed for treating female urinary incontinence; and E-Wave, another type of NMES device. Zynex also provides private-label accessories, such as electrodes for conducting electrical currents to the body and batteries for powering electrotherapy products. Beyond its own manufactured goods, the company acts as a distributor for several third-party medical items. These include Comfortrac/Saunders for cervical traction, JetStream for therapeutic hot/cold applications, LSO Back Braces for lumbar support, and various knee braces. Expanding its technological portfolio, Zynex offers advanced monitoring solutions. This includes the Zynex Fluid Monitoring System (CM-1500), a non-invasive device that tracks relative fluid volume changes in surgical and recovery settings to identify fluid loss during operations or internal bleeding afterward. A wireless version, the CM-1600, provides similar non-invasive fluid volume monitoring for adult patients. Additionally, the company supplies the NiCO CO-Oximeter and the HemeOx tHb Oximeter, both non-invasive, laser-based devices for co-oximetry and total hemoglobin pulse oximetry, respectively. Zynex's diverse product range is utilized across various medical applications, including pain management, rehabilitation for stroke and spinal cord injuries, hemodynamic monitoring, and pulse oximetry. The company distributes its products primarily through its direct sales force, mainly within the United States. Established in 1996, Zynex, Inc. is based in Englewood, Colorado.
Fri, 27 Mar 2026
Zynex (ZYXI) director’s shares wiped out as Chapter 11 plan cancels equity - Stock Titan
Thu, 26 Mar 2026
Zynex (NASDAQ: ZYXI) leaves Chapter 11; new sponsor takes full control - Stock Titan
Mon, 09 Mar 2026
Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - GlobeNewswire
Tue, 27 Jan 2026
Zynex hires security amid retaliation fears as founder denied bail in fraud case - The Business Journals
Fri, 19 Dec 2025
Zynex Enters Chapter 11 and Faces Nasdaq Delisting - The Globe and Mail
Tue, 16 Dec 2025
Zynex stock plummets after filing for Chapter 11 bankruptcy protection - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 30 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 48.1 (%) |
| Held by Institutions | 13.7 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 3,380 (K) |
| EPS | -2.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.35 |
| Profit Margin | -68.4 % |
| Operating Margin | -99 % |
| Return on Assets (ttm) | -27.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -73.4 % |
| Gross Profit (p.s.) | 2.56 |
| Sales Per Share | 3.56 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | -0.1 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -0.19 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 80% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|